Boehringer Ingelheim

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
glimepiride
linagliptin
Tradjenta
type 2 diabetes
clinical trials
Flag link:
Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada
Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada
Fierce Biotech
Boehringer Ingelheim
IBM
Canada
blockchain
clinical trials
Flag link:
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
Fierce Pharma
Boehringer Ingelheim
AbbVie
biosimilars
Humira
patents
Flag link:
Boehringer taps BioMed X to source psychiatric disease research proposals
Boehringer taps BioMed X to source psychiatric disease research proposals
BioCentury
Boehringer Ingelheim
BioMed
drug discovery
psychiatric disease
Flag link:
Boehringer building out biologics manufacturing in China
Boehringer building out biologics manufacturing in China
BioPharma Dive
China
drug manufacturing
Boehringer Ingelheim
biologics
Flag link:
Bioharmony, Boehringer partner to develop antimicrobials
Bioharmony, Boehringer partner to develop antimicrobials
BioCentury
Boehringer Ingelheim
Bioharmony Therapeutics
antimicrobials
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic
Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic
Endpoints
Boehringer Ingelheim
R&D
Xynomic
mTOR
Flag link:
Boehringer employees go door-to-door delivering holiday hope to lung cancer patients
Boehringer employees go door-to-door delivering holiday hope to lung cancer patients
Fierce Pharma
Boehringer Ingelheim
patients
lung cancer
Flag link:
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Sanofi
Lantus
Eli Lilly
Boehringer Ingelheim
Mylan Labs
generics
diabetes
insulin
basal insulin
Flag link:
Boehringer Ingelheim plans to cut about 300 jobs in France
Boehringer Ingelheim plans to cut about 300 jobs in France
Yahoo/Reuters
France
Boehringer Ingelheim
layoffs
Flag link:
Boehringer dropping ex-U.S. biosimilars programs
Boehringer dropping ex-U.S. biosimilars programs
BioCentury
Boehringer Ingelheim
biosimilars
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks
BioSpace
cancer
R&D
drug development
Boehringer Ingelheim
Epizyme
Flag link:
Boehringer backs $33M cancer vaccine play at Switzerland's AMAL Therapeutics
Boehringer backs $33M cancer vaccine play at Switzerland's AMAL Therapeutics
Endpoints
vaccines
cancer vaccines
Boehringer Ingelheim
Amal Therapeutics
Switzerland
Flag link:
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
RAPS.org
Boehringer Ingelheim
AbbVie
Humira
patents
biosimilars
Flag link:
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Europe
AbbVie
Humira
Amgen
Samsung Bioepis
Mylan Labs
Novartis
Sandoz
Fresenius Kabi
Boehringer Ingelheim
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
CP Wire
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
Jardiance
Boehringer Ingelheim
Eli Lilly
Flag link:
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Tradjenta
diabetes
Flag link:

Pages